Cell>Point, Centennial, Colo, has finished second phase of its 3 part clinical trial of 99mTc-EC-G, a potential SPECT/CT imaging agent for non-small cell lung cancer (NSCLC) diagnosis.

99mTc-EC-G is Cell>Point’s cancer and cardiovascular diagnostic imaging agent.

The Phase 2 portion of the 3-part combined trial compares the efficacy and safety of 99mTc-EC-G administered and then imaged with a SPECT /CT camera to 18F-FDG contrast agent. The patient is then imaged with a PET/CT camera in the evaluation of patients with confirmed NSCLC.

The Phase 2 trial is evaluating whether diagnosing the presence of NSCLC with 99mTc-EC-G and SPECT/CT will not be inferior to diagnosing NSCLC with 18F-FDG and PET/CT.

“We are very encouraged by the favorable trends observed in imaging the primary tumor in our Phase 2 study, and therefore have closed the trial,” said David Rollo, M.D., Ph.D., Cell>Point president, in the press announcement.

More information on 99mTc-EC-G and is on the company’s website.


(Source: Website)